<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994799</url>
  </required_header>
  <id_info>
    <org_study_id>CRFB002AHU04T</org_study_id>
    <secondary_id>CRFB002DHU06T</secondary_id>
    <nct_id>NCT00994799</nct_id>
  </id_info>
  <brief_title>Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema</brief_title>
  <official_title>Comparison of the Effect of Intravitreal Ranibizumab Injections Compared to Macular Grid-pattern Laser Therapy for the Symptomatic Treatment of Diabetic Macular Edema (a Randomized, Controlled, Phase III Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Csolnoky Ferenc County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Szeged University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the hypothesis that ranibizumab injection given into the eye is an
      efficacious and safe treatment option applied for swelling of the macula (site of sharp
      vision) in diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, three-center trial to assess the efficacy and safety of
      intravitreal ranibizumab injections in diabetic macular edema. Comparator arm consists of
      patients receiving macular grid-pattern laser therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in retinal thickness as assessed with OCT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the extension of foveal avascular zone, foveal thickness and macular volume by FA and OCT, respectively.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinal function (color vision,contrast sensitivity, multifocal ERG)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>ranibizumab group</arm_group_label>
    <description>patients receiving intravitreal ranibizumab for diabetic macular edema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laser</arm_group_label>
    <description>patients receiving macular grid-pattern laser therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>10mg/ml intravitreal injection</description>
    <arm_group_label>ranibizumab group</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>macular grid-pattern laser</intervention_name>
    <description>macular grid-pattern laser therapy</description>
    <arm_group_label>laser</arm_group_label>
    <other_name>macular laser</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetes patients having clinically significant macular edema due to diabetic retinopathy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female type I or II diabetic patients over 18 years of age

          -  Diagnosis of DME secondary to diabetic retinopathy and decrease in vision is due to
             DME and not due to other causes in the opinion of the investigator

          -  Patients who have a BCVA score between 78 and 39 letters in the study eye using
             ETDRS-like visual acuity charts at a testing distance of 4 meters

          -  Expectation by the investigator that patient will potentially benefit from laser
             treatment or ranibizumab treatment

          -  Willing and able to comply with all study procedures

        Exclusion Criteria:

          -  Active intraocular inflammation, any active infection or history of uveitis

          -  Uncontrolled glaucoma or neovascularization of the iris in the study eye

          -  Structural damage within 0.5 disc diameter of the center of the macula in the study
             eye likely to preclude improvement in visual acuity following the resolution of
             macular edema, including atrophy of the retinal pigment epithelium, subretinal
             fibrosis, laser scar(s), epiretinal membrane involving fovea or organized hard exudate
             plaques

          -  Concurrent disease in the study eye that could compromise visual acuity or prevent the
             improvement of visual acuity (including diabetic proliferative retinopathy) or require
             medical or surgical intervention during the study period, including cataract, retinal
             vascular occlusion, retinal detachment, macular hole or choroidal neovascularization
             of any cause

          -  Panretinal laser photocoagulation in the study eye within 6 months prior to or during
             the study or focal/grid laser photocoagulation in the study eye within 3 months prior
             to study entry

          -  Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,
             bevacizumab, ranibizumab, etc) or intravitreal corticosteroids in the study eye within
             3 months prior to randomization

          -  Any intraocular surgery in the study eye within 3 months prior to randomization

          -  History of vitrectomy in the study eye

          -  Ocular conditions in the study eye that require chronic concomitant therapy with
             topical ocular or systemically administered corticosteroids

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lajos Kolozsvari, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szeged University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rozsa Degi, assoc prof</last_name>
    <phone>+36 30 279 4330</phone>
    <email>drdegirozsa@freemail.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara B Toth, assistlect</last_name>
    <phone>+36 30 239 3020</phone>
    <email>btothbarbara@freemail.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Semmelweis University Department of Ophthalmology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Recsan, lecturer</last_name>
      <phone>+36 30 253 6759</phone>
      <email>recsan@szem2.sote.hu</email>
    </contact>
    <investigator>
      <last_name>Zsuzsanna Recsan, lecturer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology</name>
      <address>
        <city>Szeged</city>
        <zip>H-6721</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rozsa Degi, assoc prof</last_name>
      <phone>+36 30 279 4330</phone>
      <email>drdegirozsa@freemail.hu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara B Toth, assist lect</last_name>
      <phone>+36 30 239 3020</phone>
      <email>btothbarbara@freemail.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Rozsa Degi, assoc prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara B Toth, assist lect</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc County Hospital Dept of Ophthalmolgy</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozsef Gyory, head of dept</last_name>
      <phone>+36 70 379 1622</phone>
      <email>gyjf@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jozsef Gyory, head of dept</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lajos Kolozsvari Dr Prof</name_title>
    <organization>University of Szeged Department of Ophthalmology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

